BeiGene, Junshi Bio and other leading innovative pharmaceutical companies are more willing to invest in this

【Pharmaceutical Network Market Analysis】 For enterprises on the Science and Technology Innovation Board, research and development is the lifeline of enterprises, and it is crucial
to join the investment in research and development.

As of August 31, all 98 biomedical companies on the Science and Technology Innovation Board have completed the disclosure of their 2022 semi-annual reports
.

According to the combing, the head innovative pharmaceutical companies in these enterprises are more willing to invest in research and
development.

Among them, the R&D investment of BeiGene and Junshi Biotech is more than 1 billion yuan
.

According to the data of the first half of the performance report released by BeiGene, in the first half of this year, BeiGene invested a total of 5.
02 billion yuan in research and development expenses, as of June 30, BeiGene's global R&D and medical affairs team has exceeded 3,300 people, more than 100 clinical trials have been performed in more than 45 countries and regions, and the total enrollment of patients and healthy subjects has exceeded 16,000 people, of which about half of the subjects are from overseas
.

Some institutions have released research reports saying that with the commercial expansion of BeiGene's core products BTK inhibitors and PD-1 monoclonal antibodies, as well as the expected milestones in the second half of 2022 (including the approval of new indications), BeiGene's globalization process will be verified, and it will also feed back early research and development investment
through higher sales revenue.

It is reported that at present, BeiGene has listed 16 commercial products and has a rich
product portfolio.

Looking at Junshi Biology, the R&D investment in the first half of this year was 1.
062 billion yuan, an increase of 12.
14%
year-on-year.

The total investment in research and development accounted for 112.
28% of the operating income, an increase of 67.
48 percentage points
.

Junshi Bio said that during the reporting period, the company continued to promote R&D projects according to the R&D process, continuously enriched and expanded the pipeline of products under development through independent research and development and cooperative development/equity introduction, etc.
, quickly promoted the progress of projects that have now entered the clinical stage, and actively reserved and promoted the development
of pre-clinical projects.

It is understood that Junshi biological products are mainly based on source innovation and independent research and development of biological products, and at the same time, they further enrich the product pipeline
through cooperation with biotechnology companies.

As of the date of the report, the company's pipeline of research products covers five major therapeutic areas, including malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases
.

Among them, there are 3 products under development in the commercialization stage (triprimumab, esvesvirumab and adalimumab), nearly 30 products under research are in the clinical trial stage (of which ongorecizumab, VV116, bevacizumab and PARP inhibitors are in the phase III key registered clinical trial stage), and more than 20 products under research are in the preclinical development stage
.

According to the combing, in addition to the above two enterprises, there are 12 biomedical enterprises in the science and technology innovation board who have invested more than 200 million yuan
in research and development.

They are Anxu Biologics, Lianying Medical, Rongchang Biologics, Shenzhou Cell-U, Oriental Biologics, BGI Intelligent Manufacturing, Dizhe Pharmaceutical-U, Consino, Maiwei Bio-U, Bio-U, Biotech, Zejing Pharmaceutical-U, and Yifang Bio-U
.

Among them, Anxu Biologics and Lianying Medical invested more than 500 million yuan in research and development in the first half of the year
.

Among them, The R&D investment of Anxu Bio in the first half of the year was 654 million yuan
.

The company has formed a complete set of research, development and innovation system
.

On the one hand, the company continues to iterate and improve its products in view of the diversified needs of the market and customers; On the other hand, the company actively studies the development trend of the industry, sets up different types of research topics, and independently develops new products
that are forward-looking and in line with the future development direction of the market industry.

Lianying Medical invested 506 million yuan in research and development in the first half of this year
.

It is reported that the company's core components, including high-power CT tubes, high-reliability high-voltage generators, large-capacity X-ray tubes, etc.
are already under research, and it is expected that mass production will be achieved soon in the future, and new materials and technologies will be accelerated in the research and development
of next-generation core components.

According to the data, Lianying Medical has always attached great importance to R&D investment, of which R&D investment in 2019-2021 was 690 million yuan, 850 million yuan and 1.
048 billion yuan, accounting for 23.
17%, 14.
76% and 14.
45%
of revenue, respectively.

In addition, in the first half of this year, the R&D investment of Rongchang Biology, Shenzhou Cell-U, Oriental Biologics, BGI Intelligent Manufacturing, Dizhe Pharmaceutical-U, Cansino, Maiwei Bio-U, BIT, Zejing Pharmaceutical-U, and Yifang Bio-U was 450 million yuan, 363 million yuan, 348 million yuan, 332 million yuan, 330 million yuan, 324 million yuan, 316 million yuan, 266 million yuan, 255 million yuan and 220 million yuan
, respectively.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.